COMMUNIQUÉS West-GlobeNewswire

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO
29/01/2024
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) , a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and [...]
OneMedNet Announces Participation as an Exhibitor at the 15ᵗʰ Annual SCOPE Summit
29/01/2024
MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade imaging Real World Data (“iRWD”), today announced its [...]
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
29/01/2024
PLEASANTON, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that the company is well-positioned to support [...]
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
29/01/2024
Initial interim landmark data analysis (N=50 at 24 Weeks) will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial at Angiogenesis, Exudation, and Degeneration 2024 [...]
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer
29/01/2024
REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular [...]
Madrigal Pharmaceuticals Announces Additions to Its Leadership Team
29/01/2024
CONSHOHOCKEN, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today [...]
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™
29/01/2024
U.S. patent allowance impacts Aging-related Frailty patients receiving vaccines and builds upon a growing patent estate protecting the use of Lomecel-B™ MIAMI, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: [...]
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
29/01/2024
LEXINGTON, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to [...]
DLH to Participate in Alliance Global Partners’ Virtual Technology Conference
29/01/2024
ATLANTA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital [...]
Orion publishes Financial Statement Release for 2023 and holds a webcast on 13 February 2024
29/01/2024
ORION CORPORATION PRESS RELEASE 29 January 2024 at 15.00 EET Orion publishes Financial Statement Release for 2023 and holds a webcast on 13 February 2024 Orion will publish Financial Statement Release for 2023 on [...]
Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting
29/01/2024
Oak Ridge, TN, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR) , the global leader in blood volume measurement technology, today announces it will be exhibiting at the Society of Nuclear Medicine and [...]
Corcept Appoints Roberto Vieira as President, Oncology
29/01/2024
MENLO PARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, [...]
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
29/01/2024
Findings further demonstrate that efzofitimod modulates myeloid cells via the neuropilin-2 (NRP2) receptor to promote a unique anti-inflammatory mechanism. Role of NRP2 in immune system validated by activity of NRP2 [...]
Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program
29/01/2024
Total of $100,000 Awarded to Five Patient Advocacy Organizations to Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) [...]
Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment
29/01/2024
Science 37 stockholders to receive $5.75 per share in cash RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (the “Company” or “Science 37”), the clinical research [...]
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
29/01/2024
MELBOURNE, Australia and SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
29/01/2024
The clinical trial for SCI-210 will be conducted in Israel, after which the company aims to move forward with the commercialization process of SCI-210 first in the Israeli market TEL AVIV, Israel, Jan. 29, 2024 (GLOBE [...]
Leading Veterinary Software Company Instinct Science Acquires VetMedux, Owner of Fast-Growing Clinician's Brief and Plumb’s Veterinary Drugs
29/01/2024
The acquisition brings together the industry’s foremost technology and clinical content expertise to advance the companies’ shared mission to better serve veterinary professionals DOYLESTOWN, Pa. and TULSA, Okla., Jan. [...]
Major shareholder announcement
29/01/2024
Major shareholder announcement January 29, 2024 Company announcement No. 03 On January 29, 2024, following the satisfaction of all conditions precedent, the combination of Novozymes A/S ("Novozymes") and Chr. Hansen [...]

Pages